氟西汀联合奥氮平治疗伴躯体症状抑郁症的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy and safety of Fluoxetine combined with Olanzapine in the treatment of depression with somatic symptoms. Methods Sixty-two patients with depression with physical symptoms who were treated in our hospital from February 2016 to October 2018 were enrolled. The patients were divided into observation group(n=31) and control group (n=31) according to the random number table method. The observation group was treated with Fluoxetine plus Olanzapine, the control group was treated with Fluoxetine alone, and both groups were treated continuously for 8 weeks. Before treatment and at the 2nd, 4th and 8th week of treatment, the Hamilton depression scale(HAMD) and somatic symptom severity scale (PHQ) were used to evaluate the effect. The treatment emergent symptom scale (TESS) was used to evaluate adverse reactions. Results The HAMD and PHQ scores of the observation group were lower than those of the control group at the 2nd, 4th and 8th week of treatment, the differences were statistically significant (P＜0.05). There was no significant difference in TESS score between the two groups (P＞0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). The total effective rate of the observation group was 96.77%, which was higher than that of the control group (80.64%), and the difference was statistically significant (P＜0.05). Conclusion The effect of Fluoxetine combined with Olanzapine in the treatment of depression with somatic symptoms is better than that of Fluoxetine alone, and it takes effect quickly in good safety.

Key words： Depression Physical symptoms Fluoxetine Olanzapine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Hui-ying

Cite this article:

LIU Hui-ying. Clinical effect of Fluoxetine combined with Olanzapine in the treatment of depression with somatic symptoms[J]. 中国当代医药, 2020, 27(7): 65-68.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I7/65

[1]	陆林.沈渔邨精神病学[M].6 版.北京：人民卫生出版社，2018：381-406.
[2]	江开达.精神病学高级教程[M].2 版.北京：中华医学电子音像出版社，2016：153-158.
[3]	房艳艳，周伟，赵娜，等.抗抑郁联合低剂量奥氮平对伴躯体症状抑郁症患者的影响[J].中国健康心理学杂志，2018，26（4）：488-452.
[4]	刘红霞，高彩凤，高磊，等.舍曲林联合奥氮平治疗老年抑郁症对照研究及随访[J].中国健康心理学杂志，2017，25（2）：175-178.
[5]	李玉焕，高安民，孟祥军.西酞普兰合并奥氮平治疗伴躯体障碍抑郁症的对照研究[J].精神医学杂志，2007，20（2）：91-92.
[6]	范肖东，汪向东，于欣，等.精神与行为障碍分类[M].北京：人民卫生出版社，1993：97-104.
[7]	郝伟，陆林.精神病学[M].8 版.北京：人民卫生出版社，2018：105-108.
[8]	徐韬园.现代精神医学[M].上海：上海医科大学出版社，2000：309-310.
[9]	王鹏，李会敏，张长军，等.文拉法辛与舍曲林治疗抑郁在对照研究[J].临床心身疾病杂志，2013，19（1）：37-39.
[10]	李兴贵，陈亮，金戈，等.心理干预联合抗抑郁药治疗脑卒中后抑郁的临床研究[J].神经损伤与功能重建杂志，2013，8（6）：447-449.
[11]	唐宏宇，方贻儒.精神病学[M].北京：人民卫生出版社，2014：89-102.
[12]	江开达.精神药理学[M].2 版.北京：人民卫生出版社，2011：153-163，751-755.
[13]	李凌江，马辛.中国抑郁障碍防治指南[M].2 版.北京：中华医学电子音像出版社，2015：87-91.
[14]	季建林，赵梅，王崇顺.抑郁症门诊患者躯体症状主诉及疗效比较[J].中国行为医学科学，2005，14（10）：892-896.
[15]	黄迪.小剂量奥氮平联合氟西汀治疗难治性抑郁症随机对照研究验[J].中国实用神经疾病杂志，2013，16（7）：14-16.